Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial
Titel:
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial
Auteur:
Soumerai, Jacob D Mato, Anthony R Dogan, Ahmet Seshan, Venkatraman E Joffe, Erel Flaherty, Kelsey Carter, Jason Hochberg, Ephraim Barnes, Jeffrey A Hamilton, Audrey M Abramson, Jeremy S Batlevi, Connie L Matasar, Matthew J Noy, Ariela Owens, Colette N Palomba, M Lia Kumar, Anita Takvorian, Tak Ni, Ai Choma, Morgan Friedman, Chaya Chadha, Puja Simkins, Elizabeth Ruiters, Jade Sechio, Sidney Portman, Daneal Ramos, Lauren Nolet, Natascha Mahajan, Neena Martignetti, Rosalba Mi, Joanna Scorsune, Krista Lynch, Julia McGree, Brianne Hughes, Stephanie Grieve, Clare Roeker, Lindsey E Thompson, Meghan Johnson, P Connor Roshal, Mikhail Huang, Jane Biondo, Juliana Wu, Qun Jacob, Allison Abdel-Wahab, Omar Zelenetz, Andrew D